Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy M Fleischmann

Showing results (1-10 of 66) with videos related to

Pageof 7
Sort By:
The Journal of Rheumatology. Supplement|February 5, 2005
Is there a need for new therapies for rheumatoid arthritis?Roy M Fleischmann
Seminars in Arthritis and Rheumatism|March 14, 2008
Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximabRoy M Fleischmann
Nature Reviews. Rheumatology|November 12, 2014
Rheumatoid arthritis: Developing new oral targeted therapies for RA can be challengingRoy M Fleischmann
Annals of the Rheumatic Diseases|May 22, 2020
EULAR PsA management recommendations 2019: can the recommendations be improved?Roy M Fleischmann
Rheumatic Diseases Clinics of North America|April 7, 2007
Comparison of the efficacy of biologic therapy for rheumatoid arthritis: can the clinical trials be accurately compared?Roy M Fleischmann
The Journal of Rheumatology. Supplement|September 19, 2002
Examining the efficacy of biologic therapy: are there real differences?Roy M Fleischmann
Annals of the Rheumatic Diseases|January 7, 2023
Jack pot! What can we learn about registries with respect to treatment cycling in rheumatoid arthritis?Janet E Pope, Roy M Fleischmann
Expert Opinion on Drug Safety|September 1, 2004
Considerations with the use of biological therapy in the treatment of rheumatoid arthritisRoy M Fleischmann, Imran Iqbal, Richard L Stern
Modern Rheumatology|October 10, 2006
Treatment of early rheumatoid arthritisRoy M Fleischmann, Richard L Stern, Imran Iqbal
Clinical Rheumatology|July 10, 2014
Efficacy of golimumab plus methotrexate in methotrexate-naïve patients with severe active rheumatoid arthritisPaul Emery, Roy M Fleischmann, Elizabeth C Hsia, et al.
Pageof 7

Showing results (1-10 of 66) with videos related to

Sort By:
Pageof 7
The Journal of Rheumatology. Supplement|February 5, 2005
Is there a need for new therapies for rheumatoid arthritis?Roy M Fleischmann
Seminars in Arthritis and Rheumatism|March 14, 2008
Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximabRoy M Fleischmann
Nature Reviews. Rheumatology|November 12, 2014
Rheumatoid arthritis: Developing new oral targeted therapies for RA can be challengingRoy M Fleischmann
Annals of the Rheumatic Diseases|May 22, 2020
EULAR PsA management recommendations 2019: can the recommendations be improved?Roy M Fleischmann
Rheumatic Diseases Clinics of North America|April 7, 2007
Comparison of the efficacy of biologic therapy for rheumatoid arthritis: can the clinical trials be accurately compared?Roy M Fleischmann
The Journal of Rheumatology. Supplement|September 19, 2002
Examining the efficacy of biologic therapy: are there real differences?Roy M Fleischmann
Annals of the Rheumatic Diseases|January 7, 2023
Jack pot! What can we learn about registries with respect to treatment cycling in rheumatoid arthritis?Janet E Pope, Roy M Fleischmann
Expert Opinion on Drug Safety|September 1, 2004
Considerations with the use of biological therapy in the treatment of rheumatoid arthritisRoy M Fleischmann, Imran Iqbal, Richard L Stern
Modern Rheumatology|October 10, 2006
Treatment of early rheumatoid arthritisRoy M Fleischmann, Richard L Stern, Imran Iqbal
Clinical Rheumatology|July 10, 2014
Efficacy of golimumab plus methotrexate in methotrexate-naïve patients with severe active rheumatoid arthritisPaul Emery, Roy M Fleischmann, Elizabeth C Hsia, et al.
Pageof 7